Education
About Us
Working with TipRanks
Follow Us
Skye Bioscience (SKYE)
NASDAQ:SKYE
SKYE Stock Chart & Stats
$0.82
-$0.06(-1.95%)
At close: 4:00 PM EST
$0.82
-$0.06(-1.95%)
Day’s Range― - ―
52-Week Range$0.68 - $5.75
Previous CloseN/A
Volume18.00K
Average Volume (3M)402.10K
Market Cap
$26.26M
Enterprise Value$8.15M
Total Cash (Recent Filing)$35.31M
Total Debt (Recent Filing)$321.85K
Price to Earnings (P/E)―
Beta2.98
Next Earnings
Mar 19, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding32,057,460
10 Day Avg. Volume339,377
30 Day Avg. Volume402,097
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-3.85
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$11.25Price Target Upside1271.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DurabilityAnalyst notes Phase 2a combination data showed an incremental weight-loss benefit and reduced weight regain versus GLP-1 therapy alone, supporting the drug's potential to deepen and sustain GLP-1–mediated weight loss.
Delivery And Dosing FeasibilityAnalyst highlights collaboration and formulation advances that enable higher-dose subcutaneous delivery with standard injectors, creating a practical path to test dose escalation that could improve efficacy.
Safety Profile Enabling EscalationAnalyst points to a clean safety profile with no serious adverse events in early studies, which preserves the ability to explore higher doses to enhance therapeutic effect if supported by PK/PD data.
Bears Say
Mechanism And Biomarker UncertaintyAnalyst raises concern that the mechanism driving durability is not confirmed by human biomarkers, leaving uncertainty whether human pharmacology will reproduce the pronounced dose-response seen in animals.
Monotherapy Efficacy SetbackAnalyst expresses disappointment in minimal monotherapy activity, noting that weak standalone efficacy could constrain development pathways if combination advantages fail to generalize.
Trial Design And Sample Size LimitationsAnalyst flags small sample sizes, potential selection bias, and loss of randomization across study portions, which complicate comparisons and necessitate larger, controlled trials to validate results.
Skye Bioscience News
SKYE FAQ
What was Skye Bioscience’s price range in the past 12 months?
Skye Bioscience lowest stock price was $0.68 and its highest was $5.75 in the past 12 months.
What is Skye Bioscience’s market cap?
Skye Bioscience’s market cap is $26.26M.
When is Skye Bioscience’s upcoming earnings report date?
Skye Bioscience’s upcoming earnings report date is Mar 19, 2026 which is in 38 days.
How were Skye Bioscience’s earnings last quarter?
Skye Bioscience released its earnings results on Nov 10, 2025. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.314 by -$0.006.
Is Skye Bioscience overvalued?
According to Wall Street analysts Skye Bioscience’s price is currently Undervalued.
Does Skye Bioscience pay dividends?
Skye Bioscience does not currently pay dividends.
What is Skye Bioscience’s EPS estimate?
Skye Bioscience’s EPS estimate is -0.3.
How many shares outstanding does Skye Bioscience have?
Skye Bioscience has 32,057,460 shares outstanding.
What happened to Skye Bioscience’s price movement after its last earnings report?
Skye Bioscience reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.314. Following the earnings report the stock price went up 2.817%.
Which hedge fund is a major shareholder of Skye Bioscience?
Currently, no hedge funds are holding shares in SKYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Skye Bioscience
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
SKYE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong financial health and promising Phase 2a study results highlighting the potential of Nimazumab in combination with semaglutide. However, increased R&D expenses, a larger net loss, concerns about monotherapy efficacy, and limited study enrollment were notable challenges.View all SKYE earnings summariesSKYE Stock 12 Month Forecast
Average Price Target
$11.25
▲(1271.95% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Outlook Therapeutics
―
Bioxcel Therapeutics
―
Inmune Bio
―
Lantern Pharma
―
Ownership Overview
Currently, No data available
---